Tacoma, Washington, 98418, United States
NCT Number: NCT00914121
Study Evaluating The Effect of Bosutinib (SKI-606) On Cardiac Repolarization (Rhythms Of The Heart)
The purpose of this study is to examine the effect of SKI-606 on rhythms of the heart (cardiac repolarization)
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–50 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Men or women of nonchildbearing potential; 18-50 years old; healthy as determined by the investigator, including physical examination, laboratory test results, and medical history.
Treatment and study plan
SKI-606
DrugOther names: Bosutinib
Placebo
Drugmoxifloxacin
DrugPrimary outcomes
-
Corrected QT interval, including QTcN, QTcB, and QTcF
Time frame: 6 weeks
Secondary outcomes
-
Laboratory evaluations, Vital Sign measurements, Adverse Event reports
Time frame: 6 weeks
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
A Single Dose, Crossover, Placebo- and Moxifloxacin- Controlled Study of the Effects of Bosutinib on Cardiac Repolarization in Healthy Adult Subjects
Important dates
- Study start
- 2009
- Primary completion
- 2009
- Study completion
- 2009
- First posted
- Jun 4, 2009
- Registry last updated
- Sep 2, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers
NCT07470125
Healthy Subjects
Seoul, South Korea
View Trial DetailsAvocado and Postprandial Responses
NCT06818032
Healthy, Healthy Adult
Burlington, Vermont, United States
View Trial DetailsStudy Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years
NCT00761631
Healthy Subjects
Benton, Arkansas, United States
View Trial DetailsHigh Image Matrix CT Reconstruction
NCT02610465
Cardiac-Related Conditions, Healthy Subjects
Bethesda, Maryland, United States
View Trial Details